---
title: "Lexeo Therapeutics, Inc. (LXEO.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LXEO.US.md"
symbol: "LXEO.US"
name: "Lexeo Therapeutics, Inc."
industry: "生物技术"
---

# Lexeo Therapeutics, Inc. (LXEO.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.lexeotx.com](https://www.lexeotx.com) |

## Company Profile

Lexeo Therapeutics, Inc.是一家临床阶段的基因医学公司，专注于美国高未满足需求的遗传性和获得性疾病。其产品管线包括 LX2006，一种基于 AAVrh10 的基因治疗候选药物，目前正在进行 1/2 期临床试验，以治疗弗里德里希共济失调心肌病；LX2020，一种基于 AAVrh10 的基因治疗候选药物，目前正在进行 1/2 期临床试验，旨在将功能性 plakophilin-2 (PKP2) 基因输送到心肌，以治疗 PKP2-ACM；以及 LX2021，一种基因治疗候选药物，目前处于临床前试验阶段，旨在输送功能性连接蛋白 43（Cx43）蛋白的编码序列，以治疗一组与高风险猝死...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.42 | 359/603 | - | - | - |
| PB | 3.84 | 262/603 | 4.64 | 2.60 | 1.05 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 9 | 82% |
| Overweight | 2 | 18% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.43 |
| Highest Target | 30.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/LXEO.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LXEO.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LXEO.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.